The Effect of ASTARTE™ on Recurrent Urinary Tract Infection (rUTI)
Recurrent Urinary Tract Infection
About this trial
This is an interventional health services research trial for Recurrent Urinary Tract Infection focused on measuring rUTI, Probiotic
Eligibility Criteria
Inclusion Criteria:
- Women 18-40 years of age
- Recurrent UTI (2 times UTI within 6 months or > 3 times UTI infection within one year).
- The subjects should be informed about the trial protocol.
- The subject must be able to follow the protocol, have provided voluntary consent and have signed the declaration of consent.
Exclusion Criteria:
- Pregnancy or planning pregnancy
- Breastfeeding
- Participation in another trial with probiotic the last 30 days.
- Hypersensitivity to any ingredient in the study product
- Patients primarily admitted for a disorder other than UTI
- Antibiotic treatment for any other condition than UTI at time of recruitment the last 30 days
Sites / Locations
- Gastrounit, Copenhagen University Hospital HvidovreRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
ASTARTE™ oral capsule
Placebo oral capsule
The capsule will contain a mixture of four probiotic strains with a combined potency of 5 x10^9 (CFU)/capsule: Lactobacillus crispatus LBV88, 2 x10^9 CFU/g Lactobacillus rhamnosus LBV96, 2 x10^9 CFU/g Lactobacillus gasseri LBV150N , 0.6 x10^9 CFU/g Lactobacillus jensenii LBV116, 0.4 x10^9 CFU/g Corn starch 79 mg, Magnesium salts of fatty acid 3 mg, Silicon dioxide 3 mg, Vegetal capsule size 1 DR white 75 mg, Fructooligosaccharides 30mg
The placebo oral capsules is identical to the ASTARTE™ capsules and contains Corn starch 79 mg, Magnesium salts of fatty acid 3 mg, Silicon dioxide 3 mg, Vegetal capsule size 1 DR white 75 mg, Fructooligosaccharides 30mg